https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Biomarker signatures for progressive idiopathic pulmonary fibrosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47057 Tue 13 Dec 2022 15:32:32 AEDT ]]> Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38777 Tue 08 Feb 2022 12:17:52 AEDT ]]> Gastroesophageal reflux and antacid therapy in IPF: Analysis from the Australia IPF Registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46902 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms. Conclusions: Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.]]> Tue 06 Dec 2022 16:07:24 AEDT ]]> Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46906 Tue 06 Dec 2022 16:07:23 AEDT ]]>